Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 18/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265786 | 1.00 | EGLN2 (0.61) | EGLN2EGLN1MAOA | |
| SCHEMBL522390 | 0.89 | EGLN2 (0.63) | EGLN2EGLN1MAOA | |
| SCHEMBL30274551 | 0.89 | EGLN2 (0.63) | EGLN2EGLN1MAOA | |
| SCHEMBL522391 | 0.89 | EGLN2 (0.63) | EGLN2EGLN1MAOA | |
| SCHEMBL522600 | 0.89 | EGLN2 (0.63) | EGLN2EGLN1MAOA | |
| SCHEMBL4499594 | 0.84 | EGLN2 (0.66) | EGLN2EGLN1MAOA | |
| SCHEMBL4410757 | 0.81 | EGLN2 (0.58) | EGLN2EGLN1MAOA | |
| SCHEMBL2356670 | 0.78 | EGLN1 (0.50) | EGLN2EGLN1 | |
| SCHEMBL522924 | 0.78 | EGLN1 (0.77) | EGLN2EGLN1 | |
| SCHEMBL30274444 | 0.78 | EGLN1 (0.77) | EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-11-08 | — | — | US | disclosed |
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | FRED HUTCHINSON CANCER RESEARCH CENTER | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | HIF1A, HIF1AN, EGLN3 | EGLN2 4/4885EGLN1 7/4885MAOA 2143/4885 |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HIF1A, HIF1AN, EGLN3 | EGLN2 4/4885EGLN1 7/4885MAOA 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.